Health Canada Approves AbbVie's SKYRIZI for Children With Psoriasis
AbbVie said Health Canada approved SKYRIZI (risankizumab) for patients aged 6 to under 18 with moderate to severe plaque psoriasis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.